CO5180628A1 - Compuestos calcioliticos - Google Patents

Compuestos calcioliticos

Info

Publication number
CO5180628A1
CO5180628A1 CO00056902A CO00056902A CO5180628A1 CO 5180628 A1 CO5180628 A1 CO 5180628A1 CO 00056902 A CO00056902 A CO 00056902A CO 00056902 A CO00056902 A CO 00056902A CO 5180628 A1 CO5180628 A1 CO 5180628A1
Authority
CO
Colombia
Prior art keywords
amino
hydroxy
phenoxy
cyano
dimethyl
Prior art date
Application number
CO00056902A
Other languages
English (en)
Inventor
Maxime Gowen
Larry J Suvan
John Fox
George B Stroup
Edward F Nemeth
Original Assignee
Smithkline Beecham Corp
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Nps Pharma Inc filed Critical Smithkline Beecham Corp
Publication of CO5180628A1 publication Critical patent/CO5180628A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para tratar una enfermedad o un trastorno caracterizados por homeostasis ósea o mineral anormal, que comprende administrar a un sujeto que necesite dicho tratamiento una cantidad efectiva de un compuesto calciolítico conjuntamente con una cantidad efectiva de un agente anti-resorción.Un método según la reivindicación 1, en el que el compuesto calciolítico se selecciona del grupo constituido por:hidrocloruro de N-[(2R-hidroxi-3-[(3-cIoro-2-ciano)fenoxi-propil]-1,1-dimetil-2-(2-naftil)-etil-amina;hidrocloruro de N-[(2R-hidroxi-3-[(3-cloro-2-ciano)fenoxi-propil]-1,1-dimetil-2-( 4-metoxifenil)etil-amina;hidrocloruro de N-[(2R-hidroxi-3-[(2,3-dicloro)fenoxi-propil]- 1,1-dimetil-2-(4-metoxifenil)etil-amina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)suIfoniI]amino]fenoxi]propiI]-1,1-dimetil-2-(6-(1,2,3,4-tetrahidronaftil)etilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)suIfonil]amino]fenoxi]propiI]-1,1-dimetil-2-(benzotien-3-il)-etilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)suIfoniI]amino]fenoxi]propiI]-1,1-dimetil-2-(benzotien-2-il)-etilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifenil)suIfonil]amino]fenoxi]propil]-1,1-dimetiI-2 (decahidronaftalen-2-iI)etilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)sul- fonil]amino]fenoxi]propil]-1,1-dimetil-4-fenilbutilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)sul- fonil]amino]fenoxi]propiI]-1,1-dimetil-4-(2-metoxifenil)butila-mina;N-[2R-hidroxi-3-[[2-ciano-4-[N-metiI-N-[4-etilcarboxifeniI]-sulfoniI]amino]fenoxi]propil]-1,1-dimetil-2-(2-naftil)etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[N-metil-N-[3-metiIcarboxime-toxifeniI]suIfonil]-amino]fenoxi]propil]-1,1-dimetil-2-(2-naftil)etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsuIfonil]-N-[[[1-[2-[6-metil]amino]piridiI]etiI]amino]-fenoxi]propil]-1,1-dimetil-2-[2-naftil]etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsulfonil]-N-[[[1-[2-[6-metil]amino]piridil]etil]amino]-fenoxi]propil]-1,1-dimetil-2-(1,2,3,4-tetrahidronaft-6-il)etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsuIfonil]-N-[[[1-[2-[6-metiI]amino]piridil]etiI]amino]-fenoxi]propil]-1,1-dimetil-2-(benzotien-3-il)-etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsulfoniI]-N-[[[1-[2-[6-metil]amino]piridil]etil]amino]-fenoxi]propil]-1,1-dimetil-2-(benzotien-2-il)-etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsulfonil]-N-[[[1-[2-[6-metiI]amino]-piridil]etiI]amino]-fenoxi]propil]-1,1-dimetil-2-(decahidronaftalen-2-il)etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsulfonil]-N-[[[1-[2-[6-metil]amino]piridil]etil]amino]-fenoxi]propil]-1,1-dimetil-4-(2-metoxifenil)butilamina; ....
CO00056902A 1999-07-31 2000-07-28 Compuestos calcioliticos CO5180628A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14677899P 1999-07-31 1999-07-31

Publications (1)

Publication Number Publication Date
CO5180628A1 true CO5180628A1 (es) 2002-07-30

Family

ID=22518969

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00056902A CO5180628A1 (es) 1999-07-31 2000-07-28 Compuestos calcioliticos

Country Status (21)

Country Link
EP (1) EP1200076A4 (es)
JP (1) JP2003505502A (es)
KR (1) KR20020016928A (es)
CN (1) CN1367687A (es)
AU (1) AU764716B2 (es)
BR (1) BR0012921A (es)
CA (1) CA2380081A1 (es)
CO (1) CO5180628A1 (es)
CZ (1) CZ2002360A3 (es)
EC (1) ECSP003590A (es)
HK (1) HK1046238A1 (es)
HU (1) HUP0202167A3 (es)
IL (1) IL147875A0 (es)
MX (1) MXPA02001204A (es)
NO (1) NO20020466L (es)
PE (1) PE20010459A1 (es)
PL (1) PL353318A1 (es)
TR (1) TR200200278T2 (es)
UY (1) UY26265A1 (es)
WO (1) WO2001008673A1 (es)
ZA (1) ZA200200784B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
UY28089A1 (es) 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
TW200845956A (en) 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN108420814A (zh) * 2017-02-15 2018-08-21 四川大学 一种nps-2143用于抗菌的新用途
CN116173187B (zh) * 2023-03-14 2024-05-10 哈尔滨医科大学 降钙素在制备防治支架内再狭窄药物中的应用、药物涂层支架及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG99290A1 (en) * 1996-04-09 2003-10-27 Nps Pharma Inc Calcilytic compounds
AR018177A1 (es) * 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento

Also Published As

Publication number Publication date
BR0012921A (pt) 2002-06-18
HUP0202167A3 (en) 2006-07-28
CN1367687A (zh) 2002-09-04
WO2001008673A1 (en) 2001-02-08
CA2380081A1 (en) 2001-02-08
UY26265A1 (es) 2001-03-16
JP2003505502A (ja) 2003-02-12
ZA200200784B (en) 2003-01-29
EP1200076A4 (en) 2005-02-09
TR200200278T2 (tr) 2002-06-21
PL353318A1 (en) 2003-11-17
CZ2002360A3 (cs) 2002-10-16
KR20020016928A (ko) 2002-03-06
EP1200076A1 (en) 2002-05-02
NO20020466L (no) 2002-03-20
IL147875A0 (en) 2002-08-14
ECSP003590A (es) 2002-02-25
MXPA02001204A (es) 2004-05-21
NO20020466D0 (no) 2002-01-29
AU764716B2 (en) 2003-08-28
PE20010459A1 (es) 2001-06-11
AU6504100A (en) 2001-02-19
HK1046238A1 (zh) 2003-01-03
HUP0202167A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
CO5180628A1 (es) Compuestos calcioliticos
KR960702846A (ko) 우로키나제 리셉터 활성의 펩티드 저해인자(peptide inhbitors of urokinase receptor activity)
BRPI0109131B8 (pt) dna, vetor de expressão compreendendo o mesmo, fator viii modificado de porcino, seu processo de produção e composição terapêutica compreendendo o mesmo
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
BR0312697A (pt) Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento
AR035158A1 (es) Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos
EP1410804A4 (en) CANCER VACCINE WITH CANCER ANTIGENS BASED ON TUMOR SUPPRESSOR GEN WT1 PRODUCT AND CATIONIC LIPOSOME
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
UY25713A1 (es) Método para tratar diabetes empleando un inhibidor ap2 y combinación.
PT93082A (pt) Processo de producao de um derivado de activador de plaminogenio tissular, de plasmideo de expressao e de medicamento contendo o referido derivado
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
BRPI0211635B8 (pt) composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica
FR2581382B1 (fr) Derives n-(quinolyl) glycinamides, leur procede de preparation et leur application therapeutique en tant que psychotropes
Yu et al. Changes in serum FSH, LH and ovarian follicular growth during electroacupuncture for induction of ovulation
FI851752L (fi) 2-amino-3-etoxikarbonylamino-6 -(p-fluorbenzylamino) pyridinglukonat och farmaceutiska produkter som innehaoller detta aemne.
ES2066913T3 (es) Derivados de cromano.
SE9702066D0 (sv) A new salt
Breusch et al. Significance of jet lavage for in vitro and in vivo cement penetration
Kehrl et al. Dexpanthenol nasal spray as an effective therapeutic principle for treatment of rhinitis sicca anterior
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
MX9702037A (es) Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.
Tremollieres et al. Transitory bone loss during substitution treatment for hypothyroidism. Results of a two year prospective study
Ruiz de Galarreta et al. Comparative study of the use of manual and mechanical suturing in the closure of the mucosal defect in total laryngectomy
Fischer et al. Adrenergic and non-adrenergic vasoconstrictor mechanisms in the human nasal mucosa.
Strano et al. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.

Legal Events

Date Code Title Description
FC Application refused